FORT WASHINGTON, Pa., May 14 /PRNewswire/ -- RPS, Inc. today announced the addition of two new members to its Senior Management Team. David A. Green, Ph.D. joins RPS as Vice President of Clinical Operations. Neil H. Shusterman, M.D. joins RPS as Senior Vice President, Medical, Regulatory and Drug Safety.
"We are pleased that both Dr. David Green and Dr. Neil Shusterman have joined the RPS organization. Both individuals bring significant industry and drug development experience that will further enhance the depth and breadth of our clinical organizational leadership and expertise," said Harris Koffer, Pharm.D., President and Chief Operating Officer. "Under their leadership, I am confident that we will continue to expand our capabilities to provide innovative, global clinical development solutions to our customers."
David A. Green, Ph.D.
In his new role, Dr. Green will have oversight of Data Management, Statistics, Programming, Site Management and Monitoring, and Project Management.
Prior to joining RPS, Dr. Green held numerous positions of increasing scope and responsibility within the bio-pharmaceutical industry. Most recently, David served as Executive Director of Clinical Field Operations for Amgen, Inc. where he led the US Clinical Field Operations and oversaw field based trial operations across Phase I-III clinical trials and all therapeutic areas. During his tenure at Amgen he was also the Therapeutic Area Operations Lead for Diabetes/Obesity, Inflammation, and General Medicine.
David brings over 15 years of clinical trial operations experience in numerous therapeutic areas primarily associated with Oncology -- Supportive Care & Therapeutics, Diabetes/Obesity, Inflammation, General Medicine, Bone Metabolism, and HIV/AIDS. He brings extensive experience in the development and management of Clinical Field Operations, Clinical Trials Operations, and Clinical Drug Development in Phases I-III.
Neil H. Shusterman, M.D.
In his new role, Dr. Shusterman will have oversight of Medical, Regulatory Affairs, Medical Writing and Drug Safety Services.
Prior to joining RPS, Dr. Shusterman was Senior Vice President of Clinical Development at the Forest Research Institute of Forest Laboratories, Inc. At Forest Laboratories he also served as Senior Vice President, Clinical Development, Safety and Operations and Vice President, Internal Medicine Therapeutic Area, Clinical Development and Medical Affairs. Before joining Forest, Dr. Shusterman held the position of Vice President, Cardiovascular Therapeutic Area, North American Medical Affairs, R&D, at GlaxoSmithKline. He brings extensive knowledge and experience in clinical research and development, as well as therapeutic expertise in internal medicine, nephrology and cardiovascular medicine.
Additionally, Dr. Shusterman has served as an adjunct Assistant Professor in the Department of Medicine at the University of Pennsylvania's School of Medicine in Philadelphia, PA, and has held Administrative Appointments such as Chief Executive Officer, University of Pennsylvania Outpatient Dialysis Unit. He is board certified in Internal Medicine and Nephrology.
RPS (ReSearch Pharmaceutical Services, Inc.), The Next Generation CRO, provides comprehensive global Phase I-IV clinical development solutions to the Pharmaceutical, Biotechnology and Medical Device industries. By combining an experienced clinical research operations infrastructure with the industry's largest resourcing engines, RPS is uniquely positioned to offer our clients both integrated and full service global outsourcing solutions.
CONTACT: Samir Shah, Vice President, Strategic Development,
email@example.com, or Marketing & Media, Sean P. Quinn, Director, Corporate
Marketing, firstname.lastname@example.org, both of ReSearch Pharmaceutical Services,
Web site: http://www.rpsweb.com/